A 68-year-old man with metastatic castration-resistant prostate cancer and widespread bone metastases as well as a history of kidney transplant, underwent 5 cycles of 177Lu–prostate-specific membrane antigen 617 therapies in our department. Being more cautious of the radiation burden imposed on the transplanted kidney, a lower average dose of 4 GBq per cycle was administered (instead of the more routine 6.0-7.4 GBq per cycle). However, excellent response was noted and serum creatinine level of 0.8 mg/dL remained stable.
From the *Department of Nuclear Medicine, Shohada e Tajrish Medical Center, School of Medicine, Shahid Beheshti University of Medical Sciences; and
†Department of Radiation Oncology, Gandi Hospital, Tehran, Iran.
Received for publication December 30, 2018; revision accepted January 12, 2019.
Conflict of interest and sources of funding: none declared.
Correspondence to: Elahe Pirayesh, MD, Address: Nuclear Medicine Department, Shohada e Tajrish Medical Center, Tajrish Sq, Tehran, Iran. E-mail: Elahe_Pirayesh@yahoo.com.